Viet Nguyen, MD
Nephrology · San Diego, CANPI 1184019051
Payments from drug & device makers
Across 20 payments — averaging $1020.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$20K
- Nxstage Medical, Inc.$33
- Avanir Pharmaceuticals, Inc.$14
- Johnson & Johnson$14
- GSK$13
Across 5 payments — averaging $1425.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$7K
What the payments were for
- Food & beverage$7491%
- Education$79%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 16 | $20,340 |
| Nxstage Medical, Inc. | 1 | $33 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| GSK | 1 | $13 |
How this compares
$20,415 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 29 | $81,789 |
| OzempicSemaglutide | 60 | $68,619 |
| JardianceEmpagliflozin | 54 | $57,035 |
| FarxigaDapagliflozin Propanediol | 29 | $33,855 |
| TrulicityDulaglutide | 15 | $26,164 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $22,034 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 44 | $20,076 |
| Sevelamer Carbonate | 60 | $18,931 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $16,032 |
| EliquisApixaban | 14 | $15,044 |
| Calcium Acetate | 46 | $5,289 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 30 | $4,891 |
| Amlodipine-AtorvastatinAmlodipine/Atorvastatin | 23 | $3,748 |
| Bumetanide | 43 | $3,441 |
| Nifedipine ErNifedipine | 34 | $1,328 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Diego
- Hui XueSan Diego$1.6M
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.